Company Description
DT Cloud Acquisition Corporation (Nasdaq: DYCQU, DYCQ, DYCQR) is a publicly traded special purpose acquisition company (SPAC) in the financial services sector. As a blank check company, DT Cloud was formed for the purpose of effecting a merger, share exchange, asset acquisition, stock purchase, reorganization or other similar business combination with one or more businesses.
The company’s units, each consisting of one ordinary share and one right, began trading on the Nasdaq Global Market under the ticker symbol DYCQU following its initial public offering. Once the securities comprising the units commenced separate trading, the ordinary shares and rights began trading under the symbols DYCQ and DYCQR, respectively. DT Cloud’s structure allows public investors to participate in a pool of capital that is intended to be deployed in a future business combination, subject to shareholder approval and other customary conditions.
Business purpose and SPAC structure
According to its public disclosures, DT Cloud’s stated objective is to complete an initial business combination with one or more operating businesses. While it may pursue a target in any industry, the company has indicated that it intends to focus its search on industries that complement its management team’s background. Until a business combination is completed, the proceeds from the initial public offering are held in a trust account, and public shareholders have the right to redeem their shares for cash in connection with certain shareholder votes.
Each unit issued in the initial public offering consists of one ordinary share and one right. Each seven rights entitle the holder to receive one ordinary share upon the consummation of the company’s initial business combination. This structure links the rights’ value to the successful completion of a transaction and is a common feature in SPAC capital structures.
Business combination with Maius Pharmaceutical
DT Cloud has announced that it entered into a definitive business combination agreement with Maius Pharmaceutical Co., Ltd., a biopharmaceutical research and development company. Under the business combination agreement, Maius is expected to become a wholly owned subsidiary of a newly formed holding company, Maius Pharmaceutical Group Co., Ltd. (“Pubco”), whose securities are expected to be listed on Nasdaq upon closing of the transaction, subject to regulatory and shareholder approvals and other customary closing conditions.
Upon consummation of the business combination, the outstanding shares of DT Cloud and Maius are expected to be converted into ordinary shares of Pubco. The business combination agreement provides for an equity value for Maius at the time of closing, and the transaction has been unanimously approved by the boards of directors of both DT Cloud and Maius, as described in the company’s public news releases. The combined company is expected to operate under the name “Maius Pharmaceutical Group Co., Ltd.” and to trade under a new ticker symbol once the transaction is completed, subject to Nasdaq approval.
Extension of combination period and shareholder approvals
As a SPAC, DT Cloud operates within a defined period in which it must complete an initial business combination or otherwise liquidate. The company’s amended and restated memorandum and articles of association originally provided for a nine-month period from the closing of its initial public offering to complete a business combination, extendable to twelve months if a business combination agreement was entered into within nine months. Following the execution of a definitive business combination agreement in October 2024, DT Cloud became entitled to this automatic three-month extension.
Subsequently, the company sought and obtained shareholder approval at several extraordinary general meetings to further extend the maximum period during which it may complete a business combination on a month-to-month basis, subject to conditions described in its proxy materials. These approvals allowed the potential extension of the combination period beyond the original termination date, with the possibility of multiple one-month extensions, and included changes to the monthly extension fee structure and related trust agreement provisions.
Nasdaq listing and compliance matters
DT Cloud’s ordinary shares and rights are listed on the Nasdaq Stock Market. According to a current report on Form 8-K, the company received deficiency letters from Nasdaq’s Listing Qualifications Department regarding the minimum Market Value of Listed Securities requirement and the minimum number of publicly held shares requirement for continued listing on the Nasdaq Global Market. The notices did not have an immediate effect on the listing of the company’s securities, and the company was afforded specified periods to regain compliance or to submit a plan to do so, in accordance with Nasdaq listing rules.
These listing-related disclosures illustrate that, like other SPACs, DT Cloud must manage both its business combination timeline and its continued listing standards as it progresses toward completing a transaction.
Corporate governance and shareholder rights
DT Cloud’s proxy materials describe proposals presented to shareholders at extraordinary general meetings, including amendments to its governing documents to extend the combination period, changes to the monthly extension fee, amendments to the investment management trust agreement, and potential adjournment proposals. Public shareholders have the right to redeem their ordinary shares for their pro rata portion of the funds held in the trust account in connection with certain proposals, regardless of how they vote, subject to the procedures and deadlines described in the company’s proxy statements.
These governance mechanisms are central features of the SPAC structure, giving public shareholders a choice between remaining invested through a business combination or redeeming their shares for cash held in trust.
Company status
Based on the available information, DT Cloud Acquisition Corporation continues to operate as a SPAC seeking to complete its initial business combination with Maius Pharmaceutical Co., Ltd., subject to the satisfaction of closing conditions, regulatory review, shareholder approvals, and listing requirements. There is no indication in the provided materials that the business combination has been completed or that the company has been delisted or liquidated.